A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) were associated with reduced rates of 3-point major adverse cardiovascular events (3P-MACE) and hospitalization for heart failure (HHF) compared to dipeptidyl peptidase 4 inhibitors (DPP-4is). Compared to GLP1-RAs, SGLT-2is were associated with reduced rates of HHF. The study included 35,679 participants aged ≥70 years who were new users (DPP-4is: 62%, GLP1-RAs: 16%, SGLT-2is: 23%) between 2012 and 2020. In the as-treated analysis, GLP1-RAs and SGLT-2is were associated with significantly reduced rates of 3P-MACE and HHF compared to DPP-4is. The overall incidence rate ratios (IRR) for 3P-MACE was 0.68 (GLP1-RAs vs. DPP4is) and 0.65 (SGLT-2is vs. DPP4is), while for HHF the IRR was 0.81 (GLP1-RAs vs. DPP4is) and 0.60 (SGLT-2is vs. DPP4is). These effects were predominantly independent of age. Compared to GLP1-RAs, SGLT-2is were associated with a significant reduction of HHF, with an overall IRR of 0.75. No significant difference was observed between SGLT-2is and GLP1-RAs on 3P-MACE. The results confirm the cardiovascular benefits of newer glucose-lowering drugs in elderly populations and support current guidelines. Source: https://www.thelancet.com/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.